This blog explores the key areas of concern for pharmaceutical companies and some of the potential implications of these reforms.
The pharma industry may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US.
The upcoming changes to the EU’s joint procurement rules will apply in instances of ‘serious cross-border threats to health’.
Aduhelm’s US launch has prompted a new look into what is in store for the Alzheimer’s disease market over the coming years.
Give your business an edge with our leading industry insights.